{"id":208897,"name":"REVVITY, INC.","slug":"revvity-inc","state":"MA","country":"United States of America","description":"","totalSpending":1350000,"filings":24,"yearlySpending":[{"year":2021,"income":280000},{"year":2022,"income":350000},{"year":2023,"income":280000},{"year":2024,"income":280000},{"year":2025,"income":160000}],"issues":["DIS","HCR","BUD","CAW","MED","TRD","DEF","MAN","AGR","VET","MMM","PHA","INS","FOO","HOM","SCI","ENV","TAR","TAX"],"firms":["REVVITY, INC."],"lobbyists":["JORDAN COX","LUIS TOVAR"],"govEntities":["Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES","SENATE","White House Office","Bureau of Industry and Security (BIS)"],"sampleDescriptions":["SARS-CoV-2 Testing, including RT-PCR Testing, Rapid Antigen Testing, Genomic Sequencing, and T Cell Immune Response Testing, and related reimbursement and policies \nH.R. 1319, American Rescue Plan Act","SARS-CoV-2 Testing, including RT-PCR Testing, Rapid Antigen Testing, Genomic Sequencing, and T Cell Immune Response Testing, and related reimbursement and policies \nH.R. 1319, American Rescue Plan Act","SARS-CoV-2 Testing, including RT-PCR Testing, Rapid Antigen Testing, Genomic Sequencing, and T Cell Immune Response Testing, and related reimbursement and policies \nH.R. 1319, American Rescue Plan Act","SARS-CoV-2 Testing, including RT-PCR Testing, Rapid Antigen Testing, Genomic Sequencing, and T Cell Immune Response Testing, and related reimbursement and policies \nH.R. 1319, American Rescue Plan Act","SARS-CoV-2 Testing, including RT-PCR Testing, Rapid Antigen Testing, Genomic Sequencing, and T Cell Immune Response Testing, and related reimbursement and policies \nH.R. 1319, American Rescue Plan Act"],"years":[2021,2022,2023,2024,2025]}